Key result
The monovalent rotavirus vaccine (RV1) was 94% effective against G9P[4] rotavirus-related hospitalization.
Why the study?
Does monovalent rotavirus vaccine (RV1) prevent severe rotavirus gastroenteritis caused by the G9P[4] strain in Mexican children under 5 years of age?
Case-Control
Yes
Does monovalent rotavirus vaccine (RV1) prevent severe rotavirus gastroenteritis caused by the G9P[4] strain in Mexican children under 5 years of age?
The monovalent rotavirus vaccine provides high protection against severe gastroenteritis caused by the emerging heterotypic G9P[4] strain, indicating the strain's emergence is likely not due to vaccine pressure.
Answers are grounded in this paper and cite their sources.
Supports RV1 against emerging G9P[4] strains; challenges vaccine pressure as emergence driver in observational data.
After the introduction of monovalent rotavirus vaccine (RV1) in Mexico in 2006-2007, diarrhea mortality and morbidity declined substantially among Mexican children under 5 years of age. In January 2010, surveillance identified the emergence of a novel G9P[4] rotavirus strain nationwide. We conducted a case-control study to assess the field effectiveness of RV1 against severe rotavirus gastroenteritis caused by this unusual strain and to determine whether the G9P[4] emergence was related to vaccine failure or failure to vaccinate. RV1 was 94% effective (95% confidence interval, 16%-100%) against G9P[4] rotavirus-related hospitalization, indicating that its emergence was likely unrelated to vaccine pressure.
No takes yet. Share an insight, caveat, or question.
Yen et al. (2011) conducted a case-control in Severe rotavirus gastroenteritis. Monovalent rotavirus vaccine (RV1) was evaluated on G9P[4] rotavirus-related hospitalization (94% effective, 95% CI 16%-100%). The monovalent rotavirus vaccine (RV1) was 94% effective against G9P[4] rotavirus-related hospitalization.
Synapse has enriched 10 related papers. Consider them for comparative context: